Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock

Viridian Therapeutics announced concurrent public offerings aiming to raise $250 million through $150 million in convertible senior notes due 2032 and $100 million in common and preferred stock. Net proceeds are designated to repay all outstanding indebtedness with Hercules Capital, fund market expansion studies for its TED franchise, and advance earlier pipeline programs.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.